Medexus Pharmaceuticals Inc (TO:MDP) — Market Cap & Net Worth
Market Cap & Net Worth: Medexus Pharmaceuticals Inc (MDP)
Medexus Pharmaceuticals Inc (TO:MDP) has a market capitalization of $92.76 Million (CA$128.23 Million) as of April 18, 2026. Listed on the TO stock exchange, this Canada-based company holds position #21307 globally and #542 in its home market, demonstrating a 2.58% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Medexus Pharmaceuticals Inc's stock price CA$3.97 by its total outstanding shares 32300380 (32.30 Million).
Medexus Pharmaceuticals Inc Market Cap History: 2015 to 2026
Medexus Pharmaceuticals Inc's market capitalization history from 2015 to 2026. Data shows change from $92.88 Million to $92.76 Million (-0.01% CAGR).
Medexus Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Medexus Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.63x
Medexus Pharmaceuticals Inc's market cap is 0.63 times its annual revenue
Latest Price to Earnings (P/E) Ratio
30.26x
Medexus Pharmaceuticals Inc's market cap is 30.26 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $105.15 Million | $2.89 Million | -$1.77 Million | 36.39x | N/A |
| 2017 | $99.89 Million | $4.65 Million | -$1.37 Million | 21.46x | N/A |
| 2018 | $112.15 Million | $7.75 Million | -$2.70 Million | 14.47x | N/A |
| 2019 | $92.06 Million | $25.36 Million | -$4.88 Million | 3.63x | N/A |
| 2020 | $160.05 Million | $52.43 Million | -$4.70 Million | 3.05x | N/A |
| 2021 | $59.58 Million | $79.66 Million | -$28.26 Million | 0.75x | N/A |
| 2022 | $48.60 Million | $76.70 Million | -$2.88 Million | 0.63x | N/A |
| 2023 | $57.71 Million | $108.10 Million | $1.22 Million | 0.53x | 47.27x |
| 2024 | $80.84 Million | $113.05 Million | -$214.00K | 0.72x | N/A |
| 2025 | $67.99 Million | $108.33 Million | $2.25 Million | 0.63x | 30.26x |
Competitor Companies of MDP by Market Capitalization
Companies near Medexus Pharmaceuticals Inc in the global market cap rankings as of April 18, 2026.
Key companies related to Medexus Pharmaceuticals Inc by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #430 globally with a market cap of $53.93 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #443 globally with a market cap of $52.58 Billion USD ( CN¥359.33 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #519 globally with a market cap of $45.88 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #546 globally with a market cap of $43.42 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #430 | Zoetis Inc | NYSE:ZTS | $53.93 Billion | $122.38 |
| #443 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $52.58 Billion | CN¥56.33 |
| #519 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $39.96 |
| #546 | Haleon plc | NYSE:HLN | $43.42 Billion | $9.75 |
Medexus Pharmaceuticals Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Medexus Pharmaceuticals Inc's market cap moved from $92.88 Million to $ 92.76 Million, with a yearly change of -0.01%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$92.76 Million | +36.43% |
| 2025 | CA$67.99 Million | -15.90% |
| 2024 | CA$80.84 Million | +40.08% |
| 2023 | CA$57.71 Million | +18.75% |
| 2022 | CA$48.60 Million | -18.43% |
| 2021 | CA$59.58 Million | -62.77% |
| 2020 | CA$160.05 Million | +73.86% |
| 2019 | CA$92.06 Million | -17.92% |
| 2018 | CA$112.15 Million | +12.28% |
| 2017 | CA$99.89 Million | -5.00% |
| 2016 | CA$105.15 Million | +13.21% |
| 2015 | CA$92.88 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 18th, 2026 the market cap of Medexus Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $92.76 Million USD |
| MoneyControl | $92.76 Million USD |
| MarketWatch | $92.76 Million USD |
| marketcap.company | $92.76 Million USD |
| Reuters | $92.76 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Medexus Pharmaceuticals Inc
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of… Read more